Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760158 | 0.91 | CYP3A4 (0.51) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL17209571 | 0.90 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL2736145 | 0.90 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL2760150 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL13100455 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL10164423 | 0.83 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL2736233 | 0.83 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL13093538 | 0.83 | CYP3A4 (0.57) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL2736151 | 0.83 | CYP3A4 (0.57) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL17209737 | 0.83 | CYP3A4 (0.57) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C9 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.